We are live on ! Find out more
JSPRW icon

Japer Therapeutics Warrants

35 hedge funds and large institutions have $4.51M invested in Japer Therapeutics Warrants in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

40% more funds holding

Funds holding: 2535 (+10)

34% more capital invested

Capital invested by funds: $3.37M → $4.51M (+$1.15M)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
35
Holders Change
+10
Holders Change %
+40%
% of All Funds
0.71%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
4
Reduced
6
Closed
1
Calls
Puts
Net Calls
Net Calls Change

JSPRW Hedge Fund Activity: Q3 2020 in Review

35 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q3 2020, worth a combined $4.51M — up 34% from $3.37M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new JSPRW positions and 1 closed out — a net gain of 10 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was P. Schoenfeld Asset Management (PSAM), opening a new position worth an estimated $240K. The largest seller was Wolverine Asset Management, exiting entirely with an estimated $72K sold.

  • 35 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q3 2020, up from 25 in Q2 2020.
  • Funds reported $4.51M of Japer Therapeutics Warrants stock for Q3 2020, up 34% quarter-over-quarter.
  • 11 funds opened new Japer Therapeutics Warrants positions in Q3 2020 and 1 closed out, a net change of +10 holders.
  • The largest Japer Therapeutics Warrants buyer in Q3 2020 was P. Schoenfeld Asset Management (PSAM), an estimated $240K added.
  • The largest Japer Therapeutics Warrants seller in Q3 2020 was Wolverine Asset Management, an estimated $72K sold.

Based on aggregated 13F filings for Q3 2020.